Serevent, Advair, Foradil Withdrawals To Be Considered By Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pulmonary-Allergy Drugs Advisory Committee will vote July 13 whether currently available data support continued marketing of the long-acting beta-agonist bronchodilators. Committee will also consider labeling changes for formoterol concerning severe asthma exacerbations.